Recruiting NCT04935021

Clinical Study of ATTR-CM

Phase IV Interventional Transthyroxine Amyloidosis Cardiomyopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: ATTR-CM.
Who it may be relevant to: Registry conditions: Transthyroxine Amyloidosis Cardiomyopathy. Basic parameters: 18 years — 80 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: China
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Official title

Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Rate of cardiovascular death, myocardial infarction, and stroke [Time frame: 10 year]

Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
Patients who have the ability to understand the test and can cooperate with investigators

Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

China · 1 center

NCT: NCT04935021 · 2021-0132